600276 恒瑞医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入15,455,584-1.94%31,629,41627,984,60522,819,78521,275,271
减:营业总成本11,313,1403.79%23,093,09821,008,00118,214,15317,747,084
    其中:营业成本2,113,343-0.08%4,362,6563,848,1773,525,2483,486,639
               财务费用(32,392)-86.56%(406,945)(572,732)(478,390)(470,867)
               资产减值损失(18,334)94.14%(86,914)(32,538)(107,217)(146,684)
公允价值变动收益843,223657.86%173,574108,631(58,257)76,503
投资收益(63,148)184.99%(80,185)4,279(49,157)387,365
    其中:对联营企业和合营企业的投资收益(72,123)73.93%(97,143)(21,581)(72,696)(62,996)
营业利润5,087,742-1.38%8,990,0037,490,6324,909,9054,111,960
利润总额4,952,417-1.95%8,707,6267,169,6904,667,1103,968,492
减:所得税费用487,135-18.30%990,623832,695389,289153,351
净利润4,465,2820.24%7,717,0026,336,9954,277,8213,815,142
减:非控股权益(157)-103.44%5,947468(24,615)(91,233)
股东净利润4,465,4390.34%7,711,0556,336,5274,302,4363,906,375

市场价值指针
每股收益 (元) *0.680-2.86%1.1901.0000.6800.610
每股派息 (元) *----0.2000.2000.2000.160
每股净资产 (元) *9.71310.27%9.2327.1366.3445.929
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容